Taysha Gene Therapies price target lowered to $15 from $25 at BTIG

BTIG analyst Yun Zhong lowered the firm’s price target on Taysha Gene Therapies (TSHA) to $15 from $25 to reflect the dilution in the number of shares outstanding associated with the Astellas (ALPMY) deal but keeps a Buy rating on the shares. The Type B end-of-Phase 2 meeting that Taysha has scheduled with the FDA on December 13 to discuss the regulatory pathway for TSHA-120 in giant axonal neuropathy will be a critical step for the company’s transition into the commercial stage, the analyst tells investors in a research note.